REMARKS

A. <u>Background</u>

The present Amendment and Response to Restriction Requirement is in response to the Office Action mailed January 11, 2007. Claims 1-75 were pending at the time of the Office Action. Claims 2 and 44-50 have been amended. Claims 9-13, 44, 46-56, 58, and 61-75 have been withdrawn. Claims 1-8, 14-43, 45, 57, and 59-60 are now pending for consideration. Reconsideration of the application is respectfully requested in view of the above amendments to the claims and the following remarks.

B. Restriction Requirement

The Examiner has requested an election of single disclosed invention to be examined.

The Examiner has identified the inventions as follows:

Group I, claims 1-60, drawn to a cell comprising at least a first conjugate comprising a first protein and the N-terminal fragment of complementation protein and a second conjugate comprising a second protein and the C-terminal fragment of the complementation protein;

Group II, claims 61-66, 69-70, and 74, drawn to a method for detecting proteinprotein interactions using a cell;

Group III, claims 67 and 71, drawn to a method for testing compound for translocation induction;

Group IV, claims 68 and 72, drawn to a method for testing if a compound prevents translocation of protein;

Group V, claim 73, drawn to a kit for detecting antigens;

In response, Applicant elects Group I, which is drawn to claims 1-60, without traverse.

Additionally, the Office Action sets forth an election of species requirement if Group I is elected. In Group I, the elections of species are set forth as follows: a complementation protein (claims 9-20 and 24-31), partners A and B and stimulus (claims 44-50), and anchor protein (51-58). However, the Office Action did not set forth a listing of the species under the

complementation protein (claims 9-20 and 24-31), partners A and B and stimulus (claims 44-50),

or anchor protein (51-58). Thus, the following election of species has been made in accordance

to Applicant's understanding of the species under the complementation protein (claims 9-20 and

24-31), partners A and B and stimulus (claims 44-50), or anchor protein (51-58), and such

election is deemed to be in accordance with the species election set forth in the Office Action.

In response, Applicant elects Green Fluorescent Protein (GFP) as the complementation

protein, which is drawn to claims 14-31, without traverse.

In response, Applicant elects FKBP12 and FRB as partners A and B. Additionally,

Applicant elects Rapamycin as the stimulus. Such elections are drawn to claim 45, and are made

without traverse.

In response, Applicant elects a protein normally associated with nuclear material or

nuclear components as the anchor protein, which is drawn to claim 57, without traverse.

C. Proposed Claim Amendments

Please amend the claims in the manner indicated above, where an underline represents

new text, and strikeouts are used to indicate deleted text. The amendments to claims 2 and 44-50

have been made merely to correct typographical errors. Thus, Applicant submits that the

amendments to the claims do not introduce new matter and entry thereof is respectfully

requested.

D. Conclusion

In view of the foregoing, Applicant respectfully requests the Examiner's reconsideration

and allowance of claims 1-8, 14-43, 45, 57, and 59-60 as presented herein.

In the event there remains any impediment to allowance of the claims which could be

clarified in a telephonic interview, the Examiner is respectfully requested to initiate such an

interview with the undersigned.

Page 17 of 18

Application No. 10/511,468 Amendment A dated March 12, 2007 Reply to Office Action mailed January 11, 2007

Dated this <u>| Lagranger | Lagr</u>

DANA L. TANGREN Registration No. 37,246

JONATHAN M. BENNS Registration No. 53,983 Attorneys for Applicants Customer No. 022913 Telephone No. 801.533.9800

JMB:ajb W:\16778\10A.1\AJB0000000499V001.DOC